Diagnosis of nasopharyngeal carcinoma by means of recombinant Epstein-Barr virus proteins.

2.50
Hdl Handle:
http://hdl.handle.net/10541/104744
Title:
Diagnosis of nasopharyngeal carcinoma by means of recombinant Epstein-Barr virus proteins.
Authors:
Littler, Edward; Baylis, Sally A; Zeng, Y; Conway, Margaret J; Mackett, Mike; Arrand, John R
Abstract:
The immune response of patients with nasopharyngeal carcinoma to Epstein-Barr virus (EBV) antigens is diagnostic of the tumour. Existing tests use EBV antigens produced in EBV-infected lymphoblastoid cells, but the virus replicates poorly in these cells. Serum samples from 18 patients diagnosed as having nasopharyngeal carcinoma were screened by western blot analysis, enzyme-linked immunosorbent assay (ELISA), and immunofluorescence tests for antibodies to the EBV-coded alkaline deoxyribonuclease (DNase), thymidine kinase, and membrane antigen (gp340/220) produced in recombinant baculovirus or bovine papillomavirus systems. Each protein was a useful diagnostic marker for nasopharyngeal carcinoma, although in the gp340/220 ELISAs there was substantial overlap for both IgG and IgA antibodies between serum samples from nasopharyngeal carcinoma patients and those from healthy donors seropositive for EBV. The EBV thymidine kinase was the most sensitive predictor of nasopharyngeal carcinoma; all such samples showed both IgG and IgA antibody responses to this protein and all gave clearly distinct titres from those of the EBV-seropositive donors in the IgA test. Each of the recombinant systems described is suitable for use in large-scale screening programmes for the early diagnosis of nasopharyngeal carcinoma.
Affiliation:
Cancer Research Campaign Laboratories, Paterson Institute for Cancer Research, Christie Hospital and Holt Radium Institute, Manchester, UK.
Citation:
Diagnosis of nasopharyngeal carcinoma by means of recombinant Epstein-Barr virus proteins. 1991, 337 (8743):685-9 Lancet
Journal:
Lancet
Issue Date:
23-Mar-1991
URI:
http://hdl.handle.net/10541/104744
DOI:
10.1016/0140-6736(91)90275-T
PubMed ID:
1672175
Type:
Article
Language:
en
ISSN:
0140-6736
Appears in Collections:
All Paterson Institute for Cancer Research

Full metadata record

DC FieldValue Language
dc.contributor.authorLittler, Edwarden
dc.contributor.authorBaylis, Sally Aen
dc.contributor.authorZeng, Yen
dc.contributor.authorConway, Margaret Jen
dc.contributor.authorMackett, Mikeen
dc.contributor.authorArrand, John Ren
dc.date.accessioned2010-06-11T15:24:30Z-
dc.date.available2010-06-11T15:24:30Z-
dc.date.issued1991-03-23-
dc.identifier.citationDiagnosis of nasopharyngeal carcinoma by means of recombinant Epstein-Barr virus proteins. 1991, 337 (8743):685-9 Lanceten
dc.identifier.issn0140-6736-
dc.identifier.pmid1672175-
dc.identifier.doi10.1016/0140-6736(91)90275-T-
dc.identifier.urihttp://hdl.handle.net/10541/104744-
dc.description.abstractThe immune response of patients with nasopharyngeal carcinoma to Epstein-Barr virus (EBV) antigens is diagnostic of the tumour. Existing tests use EBV antigens produced in EBV-infected lymphoblastoid cells, but the virus replicates poorly in these cells. Serum samples from 18 patients diagnosed as having nasopharyngeal carcinoma were screened by western blot analysis, enzyme-linked immunosorbent assay (ELISA), and immunofluorescence tests for antibodies to the EBV-coded alkaline deoxyribonuclease (DNase), thymidine kinase, and membrane antigen (gp340/220) produced in recombinant baculovirus or bovine papillomavirus systems. Each protein was a useful diagnostic marker for nasopharyngeal carcinoma, although in the gp340/220 ELISAs there was substantial overlap for both IgG and IgA antibodies between serum samples from nasopharyngeal carcinoma patients and those from healthy donors seropositive for EBV. The EBV thymidine kinase was the most sensitive predictor of nasopharyngeal carcinoma; all such samples showed both IgG and IgA antibody responses to this protein and all gave clearly distinct titres from those of the EBV-seropositive donors in the IgA test. Each of the recombinant systems described is suitable for use in large-scale screening programmes for the early diagnosis of nasopharyngeal carcinoma.en
dc.language.isoenen
dc.subjectNasopharyngeal Cancer-
dc.subject.meshAntibodies, Viral-
dc.subject.meshAntigens, Viral-
dc.subject.meshCarcinoma-
dc.subject.meshDNA-Directed DNA Polymerase-
dc.subject.meshDeoxyribonucleases-
dc.subject.meshEvaluation Studies as Topic-
dc.subject.meshHerpesvirus 4, Human-
dc.subject.meshHumans-
dc.subject.meshImmunoglobulin A-
dc.subject.meshImmunoglobulin G-
dc.subject.meshMembrane Proteins-
dc.subject.meshMethods-
dc.subject.meshNasopharyngeal Neoplasms-
dc.subject.meshRecombinant Proteins-
dc.subject.meshThymidine Kinase-
dc.subject.meshViral Matrix Proteins-
dc.titleDiagnosis of nasopharyngeal carcinoma by means of recombinant Epstein-Barr virus proteins.en
dc.typeArticleen
dc.contributor.departmentCancer Research Campaign Laboratories, Paterson Institute for Cancer Research, Christie Hospital and Holt Radium Institute, Manchester, UK.en
dc.identifier.journalLanceten

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.